MedXCell SA is pleased to announce the publication of its BiorespX paper in the International Journal of Pharmaceutics

Montreux, Switzerland | April 4, 2023 – MedXCell SA, a European venture builder that specializes in cell therapy for major diseases such as cancer, autoimmune, neurological, and degenerative diseases, is pleased to announce that its paper “Novel trehalose-based excipients for stabilizing nebulized anti-SARS-CoV-2 antibody” has been published in the International Journal of Pharmaceutics and is now accessible online here.

This work describes the development of new liquid formulations of biological drugs with the potential for direct delivery via nebulization into the respiratory tract. Favouring innovation, and through an exceptional academic collaboration with the Federal Institute of Technology in Lausanne (EPFL) and academic institutions in Montpellier (CNRS, CHU Montpellier, INSERM, IRMB, ICM), MedXCell worked with researchers to conceptualize, synthesize and test a new family of functional excipient molecules with the potential to protect and enhance the activity of biological drugs (particularly antibody drugs) and thus make liquid formulation and conventional nebulizer delivery feasible.

Using the best candidate functional excipient, MedXCell was able to demonstrate successful delivery of a SARS-CoV-2 neutralizing monoclonal antibody into the entirety of the respiratory tract of experimental mice, with concomitant prophylactic and post-exposure protection from SARS-CoV-2 pathology.

MedXCell is now seeking licensees, partners or acquirers of this technology from companies with interest in delivering active biological drugs for pulmonary diseases directly to the site of action as an alternative to systemic administration (including but not limited to respiratory viruses).


MedXCell is a European venture builder with offices in Switzerland, in EU (France) and in US (Cambridge, MA) that specializes in cell therapy for major diseases such as cancer, autoimmune, neurological, and degenerative diseases. MedXCell aims to accelerate the transformation of scientific discoveries into cell therapy assets to improve human life. Leveraging European scientific excellence, MedXCell intends to create, finance, and operationally manage new start-ups arising from academic research.

MedXCell identifies or initiates commercially viable research projects with academic institutions and
develops and supports them through a co-design phase, which can help to drastically reduce project
risks before the creation of the start-up. Based on the outcome of this phase, MedXCell creates a new
entity that is well-prepared for independent financing or establishes an early strategic partnership.

For more information, please contact:

Lionel Brodard, CFO